All‐cause mortality up to 30 days · people aged 18 and over undergoing vascular surgery
It is very uncertain whether summary of findings: Fibrin sealant changes all‐cause mortality up to 30 days compared with usual care (very low certainty).
1 finding from 1 review
All‐cause mortality at 100 days post‐transplant · People undergoing autologous or HLA identical allogeneic bone marrow transplant with a variety of malignant diseases or aplastic anaemia
Summary of findings: Heparin showed no clear difference in all‐cause mortality at 100 days post‐transplant ( compared with no treatment (low certainty).
1 finding from 1 review
All‐cause mortality up to 30 days · people aged 18 and over undergoing vascular surgery
1 finding from 1 review
All‐cause mortality · post‐exacerbation COPD
Summary of Findings Table ‐ Chronic non‐invasive ventilation showed no clear difference in all‐cause mortality compared with standard treatment following a severe exacerbation (low certainty).
1 finding from 1 review
All‐cause mortality · stable COPD
Summary of Findings Table ‐ Chronic non‐invasive ventilation probably leads to lower all‐cause mortality compared with standard treatment (moderate certainty).
1 finding from 1 review
All‐cause mortality (n/N)
Summary of findings: Comparison 3 ‐ deferiprone (DFP) showed no clear difference in all‐cause mortality (n/N) compared with deferasirox (DFX) (low certainty).
1 finding from 1 review
All‐cause mortality at 100 days post‐transplant · People undergoing stem cell transplant with haematological malignancies
It is very uncertain whether summary of findings: Glutamine changes all‐cause mortality at 100 days post‐transplant ( compared with placebo (very low certainty).
1 finding from 1 review
All‐cause mortality ‐ not reported · adults with acute lymphoblastic leukaemia treated with asparaginase‐based chemotherapy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality
1 finding from 1 review
All‐cause mortality · adults with recurrent Clostridioides difficile infection (rCDI)
Summary of findings table ‐ Fecal microbiota transplantation (FMT) showed no clear difference in all‐cause mortality compared with control (low certainty).
1 finding from 1 review
All‐cause mortality ‐ not reported · farmworkers
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality at last · people with liver metastases
It is very uncertain whether summary of Findings Table ‐ Electrocoagulation alone changes all‐cause mortality at last compared with control (vehicle solution of allopurinol by mouth) (very low certainty).
1 finding from 1 review
All‐cause mortality · people at increased risk for developing type 2 diabetes
1 finding from 1 review
All‐cause mortality
1 finding from 1 review
All‐cause mortality at 100 days post‐transplant · Children undergoing stem cell transplant with malignant and non‐malignant diseases and risk factors for hepatic veno‐occlusive disease
Summary of findings: Defibrotide showed no clear difference in all‐cause mortality at 100 days post‐transplant ( compared with no treatment (low certainty).
1 finding from 1 review
Neonatal mortality · neonates born from 35 weeks of gestation who have underdone gastrointestinal surgery
1 finding from 1 review
Mortality before hospital discharge · neonates born from 35 weeks of gestation who have underdone gastrointestinal surgery
1 finding from 1 review
All‐cause mortality
1 finding from 1 review
All‐cause mortality
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Death at hospital discharge · individuals with moderate to severe disease
1 finding from 1 review